Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that members of its management team will participate in two investor conferences in August and September 2026. President and Chief Executive Officer Dr. Seth Lederman will take part in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Aug. 11 from 1:30 p.m. to 1:55 p.m. ET. The company also said Lederman will participate in one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Sept. 16. The events provide Tonix an opportunity to discuss its business and engage with the investment community.
This announcement is significant as it comes on the heels of the FDA approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. The approval marks a major milestone for Tonix, transforming it into a commercial-stage biotechnology company with a fully integrated CNS infrastructure. The company's participation in these high-profile conferences signals its intent to leverage this momentum to attract investor interest and communicate its strategic vision.
Tonix is not resting on its laurels with TONMYA. The company is actively exploring the drug's potential in Phase 2 clinical trials for major depressive disorder and acute stress disorder, expanding its therapeutic reach. Beyond TONMYA, Tonix's CNS portfolio includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder. The company is also advancing a pipeline of immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection.
The conferences provide a platform for Tonix to highlight these developments to a broader audience. The fireside chat at Canaccord Genuity and one-on-one meetings at Morgan Stanley are particularly valuable for engaging with institutional investors and analysts. These interactions are crucial for a company at Tonix's stage, as it seeks to secure the funding needed to support its commercial launch and ongoing clinical trials.
For investors, the presentations offer a chance to gain deeper insights into Tonix's commercial strategy for TONMYA, including launch execution, market access, and physician adoption. Additionally, they can learn more about the company's pipeline progress and potential catalysts, such as data readouts from ongoing trials and regulatory milestones for other candidates.
Tonix's presence at these conferences is a testament to its growing prominence in the biotech sector. The company's focus on high unmet medical needs, such as fibromyalgia, depression, and rare diseases, positions it well in a market that values innovation and patient impact. With a recently approved product and a promising pipeline, Tonix is poised to make significant strides in the coming years.
The full press release is available at https://ibn.fm/DKFAC. For more information about Tonix Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TNXP.
